Document:

Exhibit 4.1

 

SERIES A PREFERRED STOCK PURCHASE WARRANT

 

ARQULE, INC.

 

Warrant Shares: _______

 

THIS SERIES A PREFERRED
STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after November 7, 2017 (the “Initial Exercise Date”) and on or prior to the close
of business on the fourth-year anniversary of the date of the Stockholder Filing (as defined in the Purchase Agreement) (such 4th
anniversary, the “Termination Date”) but not thereafter, to subscribe for and purchase from ArQule, Inc., a
Delaware corporation (the “Company”), (i) prior to the Stockholder Filing, up to ______ shares of Series A Preferred
Stock or (ii) after the Stockholder Filing, up to ___ shares of Common Stock (together with the Series A Preferred Stock and as
subject to adjustment hereunder, the “Warrant Shares”). The purchase price for each Warrant Share shall be equal
to the Exercise Price as defined in Section 2(d).

 

Section 1.            Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the “Purchase Agreement”), dated November _, 2017, among the Company
and the purchasers signatory thereto.

 

Section 2.            Exercise.

 

(a)          Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as
it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company)
of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A
(the “Notice of Exercise”). Within two Business Days following the date of exercise as aforesaid, the Holder
shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure
specified in Section 2(e) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which
case, the Holder shall surrender this Warrant to the Company for cancellation, or alternatively an affidavit of loss in form reasonably
acceptable to the Company, within two Business Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have
the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Holder and any assignee, by acceptance of this Warrant, acknowledges and agrees that, by reason
of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

     

     

    

 

(b)          Delivery
of Securities Upon Exercise. On the Share Delivery Date (defined below), the Company shall issue the number of Warrant Shares
to which the Holder is entitled in respect of that exercise. The “Share Delivery Date” shall be on the second
Business Day following the date on which the Company has received the Notice of Exercise and payment in full of the Exercise Price
(if applicable). Notwithstanding the foregoing, in the event that the Holder’s beneficial ownership of Common Stock exceeds
the Beneficial Ownership Limitation (as defined below) or would exceed the Beneficial Ownership Limitation after giving effect
to the issuance of Common Stock issuable upon such exercise as of the Share Delivery Date, then the Company’s obligation
to issue and deliver the Warrant Shares that are so exercised shall be held in abeyance until such time as the Holder’s beneficial
ownership would be below the Beneficial Ownership Limitation (such delivery procedure, the “Delayed Delivery”).

 

(c)          Company’s
Failure to Timely Deliver Securities. If the Company shall fail to deliver the certificate or certificates representing Warrant
Shares by the Share Delivery Date, other than pursuant to a Delayed Delivery, and if on or after the Share Delivery Date the Holder
purchases (in an open market transaction or otherwise) common stock of the Company to deliver in satisfaction of a sale by the
Holder of Warrant Shares issuable upon such exercise that the Holder anticipated receiving from the Company, then the Company shall,
within three Business Days after the Holder’s request promptly honor its obligation to deliver to the Holder a certificate
or certificates representing such Warrant Shares (or, at the option of the Holder, reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored) and pay cash to the Holder in an amount equal to the excess (if
any) of the Holder’s total purchase price (including brokerage commissions, if any) for the Common Stock so purchased over
the product of (A) such number of Warrant Shares, times (B) the price at which the sell order giving rise to such purchase obligation
was executed.

 

(d)          Exercise
Price. The exercise price per share of the Series A Preferred Stock under this Warrant shall
be $1,750 and, following the Stockholder Filing, the exercise price per share of the Common
Stock under this Warrant shall be $1.75, in each case subject to adjustment hereunder (the
“Exercise Price”).

 

    2

     

    

 

(e)          Cashless
Exercise. This Warrant may be exercised, in whole or in part, at such time by means
of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares determined according
to the following formula:

 

X = Y(A-B)/A

 

Where:

 

		X =	the number of Warrant Shares that shall be issued to
the Holder;

 

		Y =	the number of Warrant Shares for which this Warrant is
being exercised (which shall include both the number of Warrant Shares issued to the Holder and the number of Warrant Shares subject
to the portion of the Warrant being cancelled in payment of the aggregate Exercise Price);

 

		A =	the Fair Market Value (determined in accordance with
the below) of one share of Common Stock (if the Warrant is being exercised after the Stockholder Filing) or one share of Series
A Preferred Stock (if the Warrant is being exercised prior to the Stockholder Filing), as applicable; and

 

		B =	the Exercise Price then in effect.

 

The Fair Market Value
per share of Common Stock or Series A Preferred Stock, as applicable, shall be determined as follows:

 

(i)          If
the Common Stock is listed on a national securities exchange, the Nasdaq Select Global Market, the Nasdaq Global Market, the Nasdaq
Capital Market, the OTC Bulletin Board or another nationally recognized trading system as of the applicable exercise date, the
Fair Market Value per share of Common Stock shall be deemed to be the reported closing sale price per share of Common Stock thereon
on the trading day immediately preceding such exercise date (provided that if no such price is reported on such day, the Fair Market
Value per share of Common Stock shall be determined pursuant to clause (ii) below).

 

(ii)         If
the Common Stock is not listed on a national securities exchange, the Nasdaq Select Global Market, the Nasdaq Global Market, the
Nasdaq Capital Market, the OTC Bulletin Board or another nationally recognized trading system as of the applicable exercise date,
the Fair Market Value per share of Common Stock shall be deemed to be the amount most recently determined by the Board to represent
the fair market value per share of the Common Stock (including without limitation a determination for purposes of granting Common
Stock options or issuing Common Stock under any plan, agreement or arrangement with employees of the Company); and, upon request
of the Holder, the Board (or a representative thereof) shall, as promptly as reasonably practicable but in any event not later
than 10 days after such request, notify the Holder of the Fair Market Value per share of Common Stock and furnish the Holder with
reasonable documentation of the Board’s determination of such Fair Market Value.

 

    3

     

    

 

(iii)        If
the Warrant is being exercised prior to the Stockholder Filing (to purchase shares of Series A Preferred Stock), then the Fair
Market Value per share of the Series A Preferred Stock as of the applicable exercise date shall be determined in good faith by
the Company and the Holder. If the Company and the Holder are unable to agree on any such determination of Fair Market Value, then
the Company and the Holder agree that a professional and reputable third party valuation firm (a “Third Party Valuation
Agent”) shall be retained by the parties, at the Company’s expense, to determine the Fair Market Value per share
of Series A Preferred Stock. In such instance, the Company and the Holder agree to request that such Third Party Valuation Firm
provide its valuation on an expedited basis (within 14 Business Days following such appointment). If the Company and the Holder
are unable to agree on a Third Party Valuation Agent, then the parties agree that the Head of the Life Sciences Practice of PricewaterhouseCoopers
shall be consulted and such person shall recommend a Third Party Valuation Agent for this purpose, and such Third Party Valuation
Agent’s determination of Fair Market Value per share of the Series A Preferred Stock shall be binding upon the Company and
the Holder.

 

Notwithstanding anything
herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to
this Section 2(e).

 

(f)          Issuance
of Warrant Shares. Holder shall be deemed to become Holder of record of the number of Warrant Shares issuable upon exercise
(and the Warrant Shares shall be deemed to have been issued) immediately before the close of business on the date or dates on which
this Warrant is exercised in compliance with this Section 2 (or if any such date is a non-Business Day, on the next succeeding
Business Day). If this Warrant is exercised, certificates or book entry notations for the Warrant Shares shall be delivered to
Holder as soon as practicable.

 

Section
3.            No Fractional Shares or Scrip. No fractional shares
or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share
which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a
cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.

 

Section 4.            No
Impairment. The Company will not, by amendment of its charter or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder against impairment. The
Company shall not close its books against the issuance of any Warrant Shares in any manner that interferes with the timely exercise
of this Warrant.

 

    4

     

    

 

Section 5.            Certain
Adjustments.

 

(a)          Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Prior to the Stockholder Filing,
any adjustments pursuant to this Section 5(a) shall take into account the number of shares of Common Stock into which each share
of Series A Preferred Stock will be converted. Any adjustment made pursuant to this Section 5(a) shall become effective
immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall
become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

 

(b)          Calculations.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(c)          Fundamental
Transactions. In connection with any Fundamental Transaction (as defined below), the Company shall make appropriate provision
so that this Warrant shall thereafter be exercisable for either (i) shares of the successor entity based upon the conversion ratio,
or (ii) other consideration, if any, payable to holders
of Warrant Shares in connection with the Fundamental Transaction. The provisions of this section shall apply similarly and
equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the exercise of this Warrant.
“Fundamental Transaction” means (A) the Company, directly or indirectly, in one or more related transactions
merges or consolidates with or into another person or entity; or (B) the Company, directly or indirectly, sells, assigns, transfers,
conveys or otherwise disposes (including by way of a license or sublicense) of all or substantially all of the properties or assets
of the Company and its subsidiaries on a consolidated basis to another person or entity; or (C) any, direct or indirect, purchase
offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the
holders of 50% or more of the outstanding Common Stock; or (D) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant
to which the Common Stock is effectively converted into or exchanged for other securities, cash or property; or (E) the Company
reorganizes, recapitalizes or reclassifies its Common Stock.

 

(d)          Notice
to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 5, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

    5

     

    

 

 

ii.         Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, concurrently with any notice provide to holders of the Company’s
Common Stock or filed with the Commission, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of
the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof
shall not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.

 

Section
6.            Compliance with Securities Laws; Disposition of Warrant
or Warrant Shares

 

(a)          Compliance
with Securities Laws. Holder, by accepting this Warrant, represents to the Company that this Warrant and the Warrant Shares
to be issued upon exercise hereof are being acquired for its own account for investment purposes only and not with a view to distribution
or resale, and that Holder will not offer, sell or otherwise dispose of this Warrant or any Warrant Shares except under circumstances
that will not result in a violation of the Securities Act of 1933, as amended (the “Act”), or any state or other
securities laws. This Warrant, any Warrant subsequently issued to Holder, and all certificates representing the Warrant Shares
issued hereunder (unless registered under the Act and any applicable state or other securities law) shall be stamped or imprinted
with a legend in substantially the following form:

 

    6

     

    

 

[THIS WARRANT HAS] [THE SECURITIES
EVIDENCED HEREBY HAVE] NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE OR OTHER SECURITIES LAWS
AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED EXCEPT (i) PURSUANT TO REGISTRATIONS THEREOF UNDER SUCH LAWS, OR (ii) IF,
IN THE OPINION OF COUNSEL THE PROPOSED TRANSFER MAY BE EFFECTED IN COMPLIANCE WITH APPLICABLE SECURITIES LAWS WITHOUT SUCH REGISTRATIONS.

 

Section
7.            Transfer of Warrant. Holder shall not assign or
transfer this Warrant or any of its rights hereunder without the prior written consent of the Company, which consent shall not
be unreasonably withheld, conditioned or delayed, except that Holder shall have the right to assign or transfer this Warrant and
all rights hereunder, in whole or in part, to (a) any affiliate of Holder, (b) any employee of any affiliate of Holder, (c) any
limited partner or other member of any affiliate of Holder one or more immediately family members of Holder or any trust for the
benefit of Holder, or (d) one or more immediate family members of Holder. Subject to the foregoing, this Warrant and all rights
hereunder are transferable, in whole or in part, at the office or agency of the Company by Holder in person or by duly authorized
attorney, upon surrender of this Warrant, together with the assignment form attached hereto as Exhibit B duly completed
and executed. Subject to the foregoing, this Warrant and all rights hereunder are transferable, in whole or in part, at the office
or agency of the Company by Holder in person or by duly authorized attorney, upon surrender of this Warrant, together with the
assignment form attached hereto as Exhibit B duly completed and executed. Upon any such permitted transfer, the Company
shall execute and deliver to the persons entitled thereto a new Warrant or Warrants of like tenor and representing the right to
purchase, in the aggregate, the same number of Warrant Shares as this Warrant then entitles Holder to purchase. The term “Warrant”
as used herein includes any such Warrant or Warrants issued by the Company to any such transferee(s). “Affiliate”
has the meaning set forth in Rule 12b- 2 of the Exchange Act.

 

Section
8.            Warrant Register. The Company shall register this
Warrant, upon records to be maintained by the Company for that purpose, in the name of the record Holder hereof from time to time.
The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise
hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section
9.            Miscellaneous.

 

(a)          No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof.

 

    7

     

    

 

(b)          Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

(c)          Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

(d)          Authorized
Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued
capital stock (i) prior to the Stockholder Filing, a sufficient number of shares of
Series A Preferred Stock, and (ii) after the Stockholder Filing, a sufficient number of shares of Common Stock, to provide
for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation, or of any requirements of the principal national securities exchange upon
which the Common Stock then may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment
for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and non-assessable and free from
all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

(e)          Law
and Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the choice of law and forum provisions of the Purchase
Agreement.

 

(f)      
    Non-waiver and Expenses. No course of dealing or any delay or failure to exercise any
right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s
rights, powers or remedies.

 

(g)          Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

(h)          Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

    8

     

    

 

(i)          Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

(j)          Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

(k)          Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

(l)          Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

(m)         Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

    9

     

    

 

(n)          Holder’s
Exercise Limitation. The Company shall not issue any Warrant Shares, and a Holder shall not have the right to receive any Warrant
Shares, upon exercise of this Warrant, to the extent (and only to the extent and only for so long as), that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned
by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set
forth in the preceding sentence, for purposes of this section, beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company
is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this section applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this section, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with
the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within two Business Days confirm orally and in writing to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to
the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date
as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”
shall initially be set at 19.9% of the number of shares of common stock outstanding immediately after giving effect to the issuance
of the Warrant Shares being exercised hereunder, provided that the Holder may increase, decrease or waive the Beneficial Ownership
Limitation upon providing the Company with written notice of such action at least 61 days’ in advance of effectiveness (provided
that no such 61-day notice period shall be required for an amendment or waiver of the Beneficial Ownership Limitation following
the Company’s initial public announcement of the pendency or proposed consummation of a Fundamental Transaction not initiated
or controlled by the Holder.

 

*        *        *

 

    10

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	ARQULE, INC.
	 	 
	 	By: 	 
	 	 	Name
	 	 	Title

 

    11

     

    

 

Exhibit A

 

NOTICE OF EXERCISE

 

TO:ARQULE, INC.

 

		1.	The undersigned hereby elects to purchase __________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any;

 

		2.	Payment will be made in lawful money of the United States;
or

 

		3.	In accordance with the formula set forth in Section 2(e),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in Section 2(e).

 

		4.	Please issue a certificate or certificates representing
said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 

 

The Warrant Shares shall be delivered to
the following DWAC Account Number or by physical delivery of a certificate to:

 

	 	 
	 	 
	 	 
	 	 
	 	 

 

		5.	Accredited Investor. The undersigned certifies that it
is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

Name of Investing Entity:

 

Signature of Authorized Signatory of Investing
Entity:

 

Name of Authorized Signatory:

 

Title of Authorized Signatory:

 

Date:

 

     

     

    

 

Exhibit B

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute
this form and supply required information. Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED,
[____] all of or [____] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	 	 whose address is

 

	.
	 
	 

 

Dated: _________________, ____

 

Holder’s Signature:

	 	 

 

Holder’s Address:

 

	 	 

 

	 	 

 

	Signature Guaranteed:  	 

 

NOTE: The signature
to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit 10.1	EXECUTION COPY

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of November 5, 2017, between ArQule, Inc., a Delaware corporation (the
“Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser”
and collectively the “Purchasers”).

 

WHEREAS, subject to the
terms and conditions set forth in this Agreement, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

 

NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of
which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE
I. 

DEFINITIONS

 

1.1           Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Agreement”
shall have the meaning ascribed to such term in the Preamble.

 

“Blackout
Period” shall have the meaning ascribed to such term in Section 4.8 (l).

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.

 

“Certificate
of Designations” means the Certificate of Designations of Series A Preferred Stock of the Company, in the form attached
hereto as Exhibit A.

 

“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.

 

“Closing
Date” means November 7, 2017, or such later date as may be mutually agreed by the parties hereto.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.01 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.

 

     

     

    

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Company”
shall have the meaning ascribed to such term in the Preamble.

 

“Company
Counsel” means Arnold & Porter Kaye Scholer LLP, with offices located at 601 Massachusetts Ave. NW, Washington, D.C.
20001.

 

“DGCL”
means the Delaware General Corporation Law.

 

“DTC”
shall have the meaning ascribed to such term in Section 4.8(m).

 

“Effectiveness
Date” shall have the meaning ascribed to such term in Section 4.8(c).

 

“Environmental
Laws” shall have the meaning ascribed to such term in Section 3.1(k).

 

“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(o).

 

“Event”
shall have the meaning ascribed to such term in Section 4.8(d).

 

“Event
Date” shall have the meaning ascribed to such term in Section 4.8(d).

 

“Event
Payments” shall have the meaning ascribed to such term in Section 4.8(d).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(g).

 

“Hazardous
Materials” shall have the meaning ascribed to such term in Section 3.1(k).

 

“Initial
Exercise Date” means the Closing Date.

 

“Intellectual
Property” shall have the meaning ascribed to such term in Section 3.1(n).

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other material restriction.

 

“Material
Adverse Effect” shall have the meaning ascribed to such term in Section 3.1(a).

 

    	 	-2-	 

     

    

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(l).

 

“Money
Laundering Laws” shall have the meaning ascribed to such term in Section 3.1(w).

 

“OFAC”
shall have the meaning ascribed to such term in Section 3.1(x).

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Pontifax”
shall have the meaning ascribed to such term in Section 4.11(a)(i).

 

“Preferred
Stock” means the series A preferred stock of the Company, par value $0.01 per share, which shall be automatically converted
on a per share basis into such number of shares of Common Stock as is set forth in the Certificate of Designations.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.

 

“Prospectus”
shall have the meaning ascribed to such term in Section 4.8 (a).

 

“Purchaser”
shall have the meaning ascribed to such term in the Preamble.

 

“Purchaser
Nominee” shall have the meaning ascribed to such term in Section 4.11(a)(i).

 

“Qualifying
Ownership Interest” shall have the meaning ascribed to such term in Section 4.11(e).

 

“Registrable
Securities” shall have the meaning ascribed to such term in Section 4.8 (a).

 

“Registration
Date” shall have the meaning ascribed to such term in Section 4.8(a).

 

“Regulation
FD” means Regulation FD promulgated by the Commission pursuant to the Exchange Act, as such Regulation may be amended
or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the
same purpose and effect as such Regulation.

 

“Removal
Date” shall have the meaning ascribed to such term in Section 4.8(m).

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(d).

 

“Resale
Registration Statement” shall have the meaning ascribed to such term in Section 4.8 (a).

 

    	 	-3-	 

     

    

 

“Restrictive
Legend” shall have the meaning ascribed to such term in Section 3.2(g)(v).

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(g).

 

“Securities”
means the Shares, the Warrants and the Warrant Shares.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Shares”
means the shares of Preferred Stock of the Company purchased hereunder in such amount as specified below such Purchaser’s
name on the signature page of this Agreement and next to the heading “Shares”.

 

“Share
Price” means an amount equal to 1,000 times $1.135.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

 

“Stockholder
Filing” means the filing by the Company, and effectiveness of an amended and restated Certificate of Incorporation duly
approved by the stockholders of the Company in accordance with applicable law, of the Company’s Certificate of Incorporation
and Bylaws pursuant to which the number of shares of Common Stock authorized thereunder is increased, to be completed not later
than five (5) Business Days from the approval of the stockholders of the Company of such amendment to the Company’s Certificate
of Incorporation.

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares and the Warrant Shares and purchased
hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription
Amount,” in United States dollars and in immediately available funds.

 

“Suspension”
shall have the meaning ascribed to such term in Section 4.8 (f).

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the Nasdaq Global Market (or any successor to any of the foregoing).

 

“Transaction
Documents” means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.

 

“Transfer
Agent” means American Stock Transfer & Trust Company, the current transfer agent of the Company, with a mailing address
of 6201 15th Avenue, Brooklyn, New York 11219, and any successor transfer agent of the Company.

 

    	 	-4-	 

     

    

 

“Warrants”
means, collectively, the Preferred Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section
2.1 hereof, which Warrants shall be exercisable beginning from the Initial Exercise Date and have a term of exercise equal to four
(4) years from the date of the Stockholder Filing.

 

“Warrant
Shares” means the shares of Preferred Stock issuable upon exercise of the Warrants.

 

ARTICLE
II. 

PURCHASE AND SALE

 

2.1           Purchase
and Sale; Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to
sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $9,500,000
of Shares and Warrants at a price equal to the Share Price. Each Purchaser’s Subscription Amount and number of Shares and
Warrant Shares purchased shall be set forth on the signature page hereto executed by such Purchaser. The Company shall deliver
to each Purchaser its respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser
shall deliver the other items set forth in Section 2.2 at the Closing. Upon satisfaction of the covenants and conditions set forth
in Sections 2.2 and 2.3, the Closing, as the case may be, shall occur at the offices of
the Company Counsel or such other location as the parties shall mutually agree.

 

2.2           Deliveries.

 

		(a)	On or prior to the Closing Date the Company shall deliver
or cause to be delivered to each Purchaser the following:

 

		(i)	this Agreement duly executed by the Company;

 

		(ii)	a copy of the irrevocable
instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, to such Purchaser, either
in book entry form in the Direct Registration System or in the form of a stock certificate, as indicated by such Purchaser, the
number of Shares set forth on the Purchaser’s signature page to this Agreement;

 

		(iii)	a Warrant, registered in the name of the Purchaser, to
purchase (i) prior to the Stockholder Filing, the number of shares of Preferred
Stock set forth on the Purchaser’s signature page to this Agreement, with an exercise price equal to $ 1,750
per share or (ii) after the Stockholder Filing, the number of shares of Common Stock equal to the product of the number of shares
of Preferred Stock multiplied by 1,000 with an exercise price of $1.75 per share, in each case subject to adjustment as
set forth therein;

 

		(iv)	an opinion of the Company’s legal counsel reasonably
satisfactory to counsel to the Purchasers, dated as of the Closing Date;

 

		(v)	a duly signed Certificate
of Designations; and

 

    	 	-5-	 

     

    

 

		(vi)	a certificate by an officer of the Company certifying that
the closing conditions in Section 2.3(a) have been met.

 

		(b)	On or prior to the Closing Date, each Purchaser shall deliver
or cause to be delivered to the Company the following:

 

		(i)	this Agreement duly executed by such Purchaser; and

 

		(ii)	funds equal to such Purchaser’s Subscription Amount
by wire transfer to the account specified in writing by the Company or as otherwise directed by the Company for delivery to the
account of the Company to be delivered promptly upon Closing.

 

2.3           Closing
Conditions.

 

		(a)	The obligations of the Company hereunder in connection
with the Closing are subject to the following conditions being met:

 

		(i)	the accuracy in all material respects on the Closing Date
of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they
shall be accurate as of such date);

 

		(ii)	all obligations, covenants and agreements of each Purchaser
required to be performed at or prior to the Closing Date shall have been performed or waived; and

 

		(iii)	the delivery by each Purchaser of the items set forth in
Section 2.2(b) of this Agreement.

 

		(b)	The respective obligations of the Purchasers hereunder
in connection with the Closing are subject to the following conditions being met, any one or more of which may be waived in whole
or in part by the Purchasers:

 

		(i)	the accuracy in all material respects on the Closing Date
of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they
shall be accurate as of such date);

 

		(ii)	all obligations, covenants and agreements of the Company
required to be performed or waived at or prior to the Closing Date shall have been performed;

 

		(iii)	the delivery by the Company of the items set forth in Section
2.2(a) of this Agreement;

 

		(iv)	no Material Adverse Effect with respect to the Company
since the date hereof shall have occurred;

 

    	 	-6-	 

     

    

 

		(v)	no voluntary or involuntary Proceeding for the reorganization,
bankruptcy, dissolution or winding up of the Company shall have occurred; and

 

		(vi)	from the date hereof to the Closing Date, trading in the
Common Stock shall not have been suspended by the Commission or the Company’s principal Trading Market, and, at any time
prior to the Closing Date trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited,
or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market,
nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have
occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its
effect on any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable
to purchase the Shares at the Closing.

 

ARTICLE
III. 

REPRESENTATIONS AND WARRANTIES

 

3.1           Representations
and Warranties of the Company. The Company hereby makes the following representations and warranties to each Purchaser as of
the date hereof and the Closing Date:

 

(a)          Organization
and Qualification. The Company is an entity duly incorporated, validly existing and in good standing under the laws of the
state of Delaware, with the requisite corporate power and authority to own and use its properties and assets and to carry on its
business as currently conducted. The Company is not in violation nor default of any of the provisions of its certificate or articles
of incorporation, bylaws or other organizational or charter documents. The Company is duly qualified to conduct business and is
in good standing as a foreign corporation in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be,
could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability
of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition
(financial or otherwise) of the Company or (iii) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse
Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to
revoke, limit or curtail such power and authority or qualification.

 

    	 	-7-	 

     

    

 

(b)          Authorization;
Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith
or therewith (including, without limitation, for purposes of Section 203 of the DGCL) other than in connection with the Required
Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been)
duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and
binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.

 

(c)          No
Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice
or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse
of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other
understanding to which the Company is a party or by which any property or asset of the Company is bound or affected, or (iii) subject
to the Required Approvals, conflict with or result in a violation of Section 203 of the DGCL or any other law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject
(including, without limitation, federal and state securities laws and regulations), or by which any property or asset of the Company
is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to
result in a Material Adverse Effect.

 

(d)          Filings,
Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
such filings as are required to be made under applicable federal and state securities laws (collectively,
the “Required Approvals”) and (ii) after the Stockholder Filing, application(s) to the applicable Trading
Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby.

 

    	 	-8-	 

     

    

 

(e)          Issuance
of the Securities. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The
Company has reserved from its duly authorized capital stock the maximum number of shares of Preferred
Stock issuable pursuant to this Agreement.

 

(f)          Capitalization.
The Company has not issued any capital stock since its most recently filed SEC Report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock
to employees pursuant to the Company’s employee stock purchase plans, the issuance of shares of Common Stock pursuant to
the Company’s at-the-market sales agreement, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act, except as disclosed in the most recently filed
SEC Report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar
right to participate in the transactions contemplated by the Transaction Documents. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

 

(g)          SEC
Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) thereof, for the
two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred
to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and
has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied
in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports,
when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial
statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent
basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements
or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit
adjustments.

 

    	 	-9-	 

     

    

 

(h)          Material
Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice (B) liabilities not required to be reflected in the Company’s
financial statements pursuant to GAAP or disclosed in filings made with the Commission and (C) non-cash accounting measures that
have effect of reducing shareholder equity, (iii) the Company has not altered its method of accounting, (iv) the Company has not
declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any
officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before
the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by
this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected
to occur or exist with respect to the Company or its businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least one Business Day prior to the date that this representation is made.

 

(i)          Compliance.
The Company is not: (i) in default under or in violation of (and no event has occurred that has not been waived that, with notice
or lapse of time or both, would result in a default by the Company), nor has the Company received notice of a claim that it is
in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to
which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived),
(ii) in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) or has been
in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign,
federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and
safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material
Adverse Effect.

 

(j)          Application
of Takeover Protections. The Company has taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement), or other
similar anti-takeover provision pursuant to its charter documents or the laws of its state of incorporation that is or could become
applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights
pursuant to the Transaction Documents.

 

(k)         Environmental Laws. The Company (i) is in compliance with all federal, state, local
and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water,
groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases
of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) has received all permits, licenses or other approvals required of it under applicable
Environmental Laws to conduct its businesses; and (iii) is in compliance with all terms and conditions of any such permit, license
or approval except where in each of clauses (i), (ii) and (iii), the failure to so comply could not be reasonably expected to have,
individually or in the aggregate, a Material Adverse Effect.

 

    	 	-10-	 

     

    

 

(l)          Regulatory
Permits. The Company possess all certificates, authorizations and permits issued by the appropriate federal, state, local or
foreign regulatory authorities necessary to conduct its businesses as described in the SEC Reports, except where the failure to
possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”),
and the Company has not received any notice of Proceedings relating to the revocation or modification of any Material Permit.

 

(m)          Title
to Assets. The Company has good and marketable title to all real property owned by it and good and marketable title in all
personal property owned by it that is material to the business of the Company, in each case free and clear of all Liens, except
for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed
to be made of such property by the Company and (ii) Liens for the payment of federal, state or other taxes, for which appropriate
reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties.
Any real property and facilities held under lease by the Company is held by it under valid, subsisting and enforceable leases with
which the Company is in compliance.

 

(n)          Intellectual
Property. The Company owns or possesses adequate rights to use all patents, patent applications, patent rights, licenses, inventions,
copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures), trademarks, trademark registrations, service marks, service mark registrations, trade names, mask work
rights and other intellectual property necessary to carry on the business now operated by it or proposed to be operated by it as
described in the SEC Reports (collectively, “Intellectual Property”), except where the lack of such ownership
or rights to use would not have a Material Adverse Effect. The Company has not received a notice (written or otherwise) that any
of the Intellectual Property has expired, terminated or been abandoned, or is essential for the Company’s business and is
expected to expire or terminate or be abandoned within one (1) year from the date of this Agreement. Except as disclosed in the
SEC Reports, or as would not, individually or in the aggregate have a Material Adverse Effect, to the best of the Company’s
knowledge, (i) there is no infringement by third parties engaged in commercial activity of any Intellectual Property of the Company
relating to the Company’s business and (ii) there are no non-commercial activities being performed by any third parties which,
upon commercialization thereof, could reasonably be expected to infringe on the Intellectual Property of the Company. The Company
has taken all reasonable actions necessary to perfect its ownership of and interest in the Intellectual Property.

 

    	 	-11-	 

     

    

 

(o)          Sarbanes-Oxley;
Internal Accounting Controls. The Company is in material compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission
thereunder that are effective as of the date hereof, as of the Closing Date. The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.
The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation
Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company.

 

(p)          Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agents or counsel with any
information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Resale Registration Statement. The Company understands and confirms that the Purchaser will rely on the foregoing representation
in effecting transactions in securities of the Company. The Company acknowledges and agrees that Purchaser makes or has made no
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section
3.2 hereof.

 

(q)          Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject
to registration under the Investment Company Act of 1940, as amended.

 

    	 	-12-	 

     

    

 

(r)          Shell
Company. The Company has never been a shell company (as defined in Rule 405 under the Securities Act).

 

(s)          No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.

 

(t)          Tax
Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company (i) has made or filed all United States federal, state and local income and all foreign income
and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes
and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods
subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.

 

(u)          Foreign
Corrupt Practices. Neither the Company, nor to the knowledge of the Company, any agent or other person acting on behalf of
the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation
of law, or (iv) violated in any material respect any provision of FCPA; except in the case of each of clauses (i) through (iv),
such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(v)          Accountants.
To the knowledge and belief of the Company, the Company’s accounting firm (i) is a registered public accounting firm as required
by the Exchange Act and (ii) has expressed, in the Company’s most recent Form 10-K, its opinion with respect to the financial
statements to be included in the Company’s Annual Report for the fiscal year ended December 31, 2016.

 

    	 	-13-	 

     

    

 

(w)          Regulation
M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company.

 

(x)          Office
of Foreign Assets Control. Neither the Company, nor to the Company’s knowledge,
any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(y)          Money
Laundering. The operations of the Company are and have been conducted at all times in compliance with applicable financial
record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”),
and no action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

3.2           Representations
and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof, as of the Closing Date to the Company as follows (unless as of a specific date therein):

 

(a)          Organization;
Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by such Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability
company or similar actions, instructions or legal agreements, as applicable, on the part of such Purchaser. Each Transaction Document
to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms
hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its
terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by the lesser of applicable law or Purchaser’s net Subscription Amount.

 

(b)          Understandings
or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation
and warranty not limiting such Purchaser’s right to sell the Securities otherwise in compliance with applicable federal and
state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.

 

    	 	-14-	 

     

    

 

(c)          Purchaser
Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, it will be either (i)
an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or
(ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act.

 

(d)          Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e)          Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it
has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment, including,
without limitation, such Purchaser’s review and discussion of the disclosure set forth in the SEC Reports, press releases
or publications related to litigation of the Company.

 

(f)          Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser’s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained in this Section 3.2(f)
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability
of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.

 

    	 	-15-	 

     

    

 

(g)          Purchaser
Acknowledgements. In connection with the purchase and sale of the Securities, each Purchaser understands and acknowledges to
the Company that:

 

		(i)	the offering and sale of the Securities has not been reviewed
or approved by the Trading Market or the Commission by reason of the parties’ intention that the offering be exempt from
registration under the Securities Act by virtue of the provisions of Section 4(a)(2) of the Securities Act;

 

		(ii)	the Company did not offer the Securities to such Purchaser
by way of general solicitation or general advertising;

 

		(iii)	the issuance of the Securities has not been qualified under
any state securities laws in reliance upon exemptions therefrom;

 

		(iv)	the Securities have not been registered under the Securities
Act and must be held indefinitely until they are subsequently registered under the Securities Act or such sale is permitted pursuant
to an available exemption from such registration requirement; and

 

		(v)	the certificate representing the Shares shall bear a legend
in substantially the following form (a “Restrictive Legend”):

 

“THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE
STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE ACT AND COMPLIANCE WITH SUCH STATE SECURITIES LAWS, (II) IN COMPLIANCE WITH RULE 144 OR ANY OTHER EXEMPTION AVAILABLE UNDER
THE ACT AND APPLICABLE STATE SECURITIES LAWS, OR (III) UPON THE DELIVERY TO ARQULE, INC. (THE “COMPANY”) OF AN OPINION
OF COUNSEL OR OTHER EVIDENCE SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION AND/ OR COMPLIANCE IS NOT REQUIRED. NOTWITHSTANDING
THE FOREGOING, THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE LOAN OR FINANCING ARRANGEMENT SECURED BY THESE SECURITIES.”

 

    	 	-16-	 

     

    

 

The Company acknowledges and agrees that in
the event that the Restrictive Legend has ceased to be applicable to the Shares held by such Purchaser, the Company shall provide
such Purchaser, at his, her or its written request, new certificates for such Shares not bearing the legend with respect to which
the restriction has ceased and terminated. The Company further acknowledges and agrees that the representations contained in this
Section 3.2 shall not modify, amend or affect such Purchaser’s right to rely on the Company’s representations and warranties
contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document
or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby.

 

ARTICLE
IV. 

OTHER AGREEMENTS OF THE PARTIES

 

4.1           Furnishing
of Information. Until the earliest of the time that no Purchaser owns Securities, the Company covenants to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act.

 

4.2           Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide the Purchaser or its agents
or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto the
Purchaser shall have executed a written agreement with the Company regarding the confidentiality and use of such information. The
Company understands and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company.

 

4.3           Use
of Proceeds. The Company shall use the net proceeds from the sale of the Securities hereunder for general corporate purposes
and shall not use such proceeds in violation of FCPA or OFAC regulations.

 

4.4           Amendment
to Certificate of Incorporation. The Company hereby agrees to seek the approval of the stockholders of the Company of an amendment
to the Company’s Certificate of Incorporation at its next annual meeting to be held no later than May 31, 2018 to increase
the number of authorized shares of Common Stock. In the event that such consent is not obtained as of the next annual meeting of
the Company, the Company hereby agrees to seek such approval at each special or annual meeting of the stockholders of the Company
thereafter until such approval is obtained.

 

4.5           Reservation
of Preferred and Common Stock. As of the date hereof, the Company has reserved and the
Company shall continue to reserve and keep available at all times, free of preemptive rights, a
sufficient number of shares of Preferred Stock for the purpose of enabling the Company to issue Warrant Shares pursuant to this
Agreement. After the Stockholder Filing, the Company shall reserve and keep available at all times, free of preemptive rights,
a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Warrant Shares pursuant to this
Agreement.

 

    	 	-17-	 

     

    

 

4.6           Listing
of Common Stock. The Company hereby agrees to use best efforts to maintain the listing
or quotation of the Common Stock on the Trading Market on which it is currently listed.

 

4.7           Certain
Transactions. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate,
agent, employee or other Person acting on its behalf or pursuant to any understanding with it will execute any Short Sales of any
of the Company’s securities during the period commencing with the execution of this Agreement and ending at such time that
such Purchaser’s Warrants have been exercised or expired, such that the Purchaser would have a net-short position in the
Company (after taking into account shares underlying the Warrants). Notwithstanding the foregoing, in the case of a Purchaser that
is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

 

4.8           Registration
Rights.

 

		(a)	Within 30 days following
the Stockholder Filing and the automatic conversion of the Preferred Stock into Common Stock in accordance with the Certificate
of Designations (the “Registration Date”), the Company shall prepare and file with the Commission a
registration statement on Form S-3 (or such other form if, at such time, the Company is not eligible to utilize such Form S-3)
covering the resale of all of the Registrable Securities from time to time on a continuous basis pursuant to Rule 415 of the Securities
Act (the “Resale Registration Statement” including the base prospectus contained therein, the “Prospectus”).
For purposes of this Section 4.8, “Registrable Securities” shall mean
(i) the Common Stock into which the Preferred Stock has been automatically converted pursuant
to the Certificate of Designations, (ii) the Common Stock underlying the Warrants, and (iii)
any other shares of Common Stock issuable with respect to the Shares by way of a
stock dividend, stock split or other distribution, or in connection with a combination of shares, recapitalization, merger, consolidation
or other reorganization; provided that such Registrable Securities shall cease to be Registrable Securities when (i) a
registration statement covering such securities has been declared effective by the Commission and such securities have been disposed
of pursuant to such effective registration statement, (ii) such securities have been sold under circumstances in which all of
the applicable conditions of Rule 144 (or any similar provisions then in force) under the Securities Act were met, (iii) such
securities are otherwise transferred and such securities may be resold without subsequent registration under the Securities Act,
or (iv) such securities shall have ceased to be outstanding.

 

    	 	-18-	 

     

    

 

		(b)	Not less than five (5) Business Days prior to the initial
filing of the Resale Registration Statement and not less than three (3) Business Days prior to the filing of any related prospectus
or any amendment or supplement thereto, the Company shall (i) furnish to the Purchasers copies of all such documents proposed
to be filed, which documents will be subject to the review and reasonable comments of the Purchasers, and (ii) cause its officers
and directors, counsel and independent registered public accountants to respond to any inquiries from the Purchasers and their
advisors. The Company shall permit one counsel designated by the Purchasers to review such Resale Registration Statement, related
prospectus, and any amendment or supplement thereto (as well as all requests for acceleration or effectiveness thereof) within
the time periods referenced above and shall use reasonable best efforts to reflect in such documents any comments as such counsel
may reasonably propose and will not request acceleration of the Resale Registration Statement without prior notice to such counsel.

 

		(c)	Upon filing the Resale Registration Statement, the Company
shall use its reasonable best efforts to cause such Resale Registration Statement to be declared effective by the Commission as
soon as practicable thereafter, including the filing of amendments and post-effective amendments and supplements to such Resale
Registration Statement, but in any event no later than 30 days following the Registration Date (or 90 days following the Registration
Date if the Resale Registration Statement will be subject to review by the Staff of the Commission), and in any event within three
Business Days following a communication from the Staff of the Commission that it has no further comments to the Resale Registration
Statement or will not review the Resale Registration Statement (as applicable, the “Effectiveness Date”). The
Company shall otherwise comply with all rules and regulations of the Commission and other governmental and regulatory authorities
applicable to the registration of such Registrable Securities and the effectiveness of the Resale Registration Statement.

 

    	 	-19-	 

     

    

 

		(d)	If: (i) the Resale Registration Statement is not filed
with the Commission on or prior to the Registration Date, (ii) the Resale Registration Statement is not declared effective by
the Commission (or otherwise does not become effective) on or prior to the Effectiveness Date or (iii) after the date the Resale
Registration Statement is declared effective by the Commission, (a) such Resale Registration Statement ceases for any reason (including
without limitation by reason of a stop order, or the Company's failure to update the Resale Registration Statement), to remain
continuously effective as to all Registrable Securities included in such Resale Registration Statement or (b) a Blackout Period
is imposed for a time period in excess of 15 consecutive or 25 aggregate Business Days during any 12-month period (any such failure
or breach in clauses (i) through (iii) above being referred to as an “Event,” and the date on which such Event
occurs being referred to as an “Event Date”), then in addition to any other rights the Purchasers may have
hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable
Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Purchaser an
amount in cash, as liquidated damages and not as a penalty, equal to 1% of the aggregate purchase price paid by such Purchaser
(“Event Payments”) pursuant to this Agreement for any unregistered Registrable Securities then held by such
Purchaser (not to exceed 6% in total). Notwithstanding the foregoing, in the event that the Company’s failure to file or
obtain the effectiveness of such Resale Registration Statement proximately results from the failure of any Purchaser to provide
the Company with information reasonably requested by the Company and necessary to complete the Resale Registration Statement in
accordance with the requirements of the Securities Act, then no such Purchaser causing the failure described above shall be entitled
to Event Payments relating to the failure caused by such Purchaser.

 

		(e)	The Company shall maintain such Resale Registration Statement
and shall comply with its other obligations under this Section 4.8 until the earlier to
occur of (i) such time as the Purchasers own no Registrable Securities and (ii) such time as the Registrable Securities may be
resold by the Purchasers pursuant to Rule 144 of the Securities Act without the requirement for the Company to be in compliance
with the current public information required under such Rule and without volume or manner-of-sale restrictions.

 

    	 	-20-	 

     

    

 

		(f)	The Company shall promptly notify the Purchasers of the
effectiveness of the Resale Registration Statement and each post-effective amendment thereto. Additionally, the Company will promptly
notify the Purchasers upon the occurrence of any of the following events in respect of the Resale Registration Statement or related
prospectus: (i) receipt of any request for additional information by the Commission or any other governmental entity during the
period of effectiveness of the Resale Registration Statement or amendments or supplements to the Resale Registration Statement
or any related prospectus; (ii) the issuance by the Commission or any other governmental entity of any stop order suspending the
effectiveness of the Resale Registration Statement or the initiation of any Proceedings for that purpose and the Company will
promptly use its reasonable best efforts to prevent the issuance of any stop order or to obtain its withdrawal at the earliest
possible moment if such stop order should be issued; (iii) receipt of any notification with respect to the suspension of the qualification
or exemption from qualification of the Registrable Securities for sale in any jurisdiction or the initiation of any Proceeding
for such purpose; (iv) the happening of any event that, in the reasonable determination of the Company and its counsel, makes
any statement made in the Resale Registration Statement or related prospectus or any document incorporated or deemed to be incorporated
therein by reference untrue in any material respect or that requires the making of any changes in the Resale Registration Statement,
related prospectus or documents so that (or the Company otherwise becomes aware of any statement included in the Resale Registration
Statement, related prospectus or document that is untrue in any material respect or that requires the making of any changes in
the Resale Registration Statement, related prospectus or document so that), in the case of the Resale Registration Statement,
it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading, and that in the case of the related prospectus, it will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading; and (v) the Company’s
reasonable determination that a post-effective amendment to the Resale Registration Statement would be appropriate (in which event
the Company will promptly make available to the Purchasers any such supplement or amendment to the Resale Registration Statement
and, as applicable, the related prospectus). In the event of any suspension of Purchasers’ ability to sell Shares pursuant
to the Resale Registration Statement as a result of the foregoing (a “Suspension”), the Company will use its
best efforts to cause the use of the prospectus so suspended to be resumed as soon as reasonably practicable after notice of a
Suspension to the Purchasers and such Suspension shall be subject to the liquidated damages provisions set forth in Section 4.8
(d) above.

 

		(g)	The Company shall furnish to the Purchasers with respect
to the Registrable Securities registered under the Resale Registration Statement such number of copies of the Prospectus (including
preliminary and supplemental prospectuses and prospectus amendments) as the Purchaser may reasonably request, in order to facilitate
the public sale or other disposition of all or any of the Registrable Securities by the Purchaser.

 

		(h)	The Company shall file documents required of the Company
for normal blue sky clearance in states as shall be reasonably appropriate in the opinion of the Company and its legal counsel;
provided, however, that the Company shall not be required to qualify to do business or consent to general service
of process in any jurisdiction in which it would not otherwise be required to qualify but for this Section 4.8
(h).

 

		(i)	All expenses incident to the Company’s compliance
with this Section 4.8, including, without limitation, all registration and filing fees,
fees and expenses of compliance with securities laws, printing expenses, filing expenses, and fees and disbursements of the Company’s
counsel and independent registered public accountants will be borne by the Company.

 

    	 	-21-	 

     

    

 

		(j)	The Company shall, at the reasonable request of any Purchaser,
prepare and file with the Commission such amendments (including post-effective amendments) and supplements to the Resale Registration
Statement and any prospectus used in connection with the Resale Registration Statement as may be necessary in order to make reasonable
changes to the plan of distribution set forth in such Resale Registration Statement.

 

		(k)	Notwithstanding anything herein to the contrary, the Purchasers’
rights under this Section 4.8 shall be automatically assignable by the Purchasers to any
permitted transferee of all or any portion of such Registrable Securities, to the extent of the Registrable Securities so transferred,
if: (i) the Purchaser agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is
furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such
transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the
securities with respect to such registration rights are being transferred or assigned, and (iii) at or before the time the Company
receives the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing to be bound
by the provisions of Section 4.8 of this Agreement. In the event that a Purchaser transfers
all or any portion of its Registrable Securities pursuant to this Section 4.8 (k), the
Company shall have ten (10) Business Days following the receipt of such notice to file any amendments or supplements necessary
to keep the Resale Registration Statement current and effective pursuant to Rule 415. Upon any such assignment, all of the transferring
Purchaser’s rights under this Agreement with respect to such transferred securities shall inure to the benefit of the transferee.

 

		(l)	If at any time following the date hereof the Resale Registration
Statement (or any subsequent registration statement registering the Registrable Securities) is not effective or is not otherwise
available for the sale of the Registrable Securities, the Company shall immediately notify the Purchasers in writing that such
registration statement is not then effective (the “Blackout Period”) and thereafter shall promptly notify such
holder when the registration statement is effective again and available. Neither the Company nor any other Person acting on its
behalf will provide a Purchaser or its agents or counsel with any information that it believes constitutes or might constitute
material, non-public information including, without limitation, the contemplated filing and timing of filing of a registration
statement.

 

    	 	-22-	 

     

    

 

		(m)	Following the Stockholder
Filing, the Restrictive Legend (or any similar restrictive legend included on the Common
Stock issued to the Purchaser following the automatic conversion of its Preferred Stock) shall be removed, and the Company
shall issue a certificate without such legend to the holder of the Securities (or Common Stock,
as applicable) upon which it is stamped or issue to such holder by electronic delivery at the applicable balance account
of The Depository Trust Company (“DTC”), if: (i) such Securities (or Common
Stock, as applicable) are registered for resale under the Securities Act, (ii) in connection with a sale, assignment or
other transfer, such holder provides the Company with an opinion of counsel, the form and substance of which opinion shall be
reasonably acceptable to the Company, that the sale, assignment or transfer of the Securities (or
Common Stock, as applicable) may be made without registration under the applicable requirements of the Securities Act or
(iii) such holder or its broker provides the Company with a broker representation letter providing to the Company any information
the Company deems necessary to determine that such sale is made in compliance with Rule 144 under the Securities Act, including,
as may be appropriate, a certification that such holder is not an affiliate of the Company (as defined in Rule 144) and a certification
as to the length of time the applicable Securities (or Common Stock, as applicable) have
been held. If the Company shall fail for any reason or for no reason to issue to the holder of the Securities within two Business
Days after the holder has provided reasonable evidence to the Company of the occurrence of any of (i) through (iii) above (the
date such evidence is provided to the Company, the “Removal Date”), a certificate without such legend to the
holder or to issue such Securities to such holder by electronic delivery at the applicable balance account at DTC (as defined
below), and if on or after such Business Day the holder purchases (in an open market transaction or otherwise) common stock to
deliver in satisfaction of a sale by the holder of such Securities (or Common Stock, as applicable)
that the holder anticipated receiving without legend from the Company, then the Company shall, within three Business Days
promptly honor its obligation to deliver to the holder a certificate or certificates representing such Securities (or
Common Stock, as applicable) and pay cash to the holder in an amount equal to the excess (if any) of the holder’s
total purchase price (including brokerage commissions, if any) for the common stock so purchased over the product of (A) such
number of Shares, times (B) the price at which the sell order giving rise to such purchase obligation was executed. Nothing herein
shall limit a Purchaser’s right to pursue any remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
shares of Common Stock as required pursuant to the terms hereof.

 

		(n)	Each Purchaser, severally and not jointly with the other
Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant to either the registration requirements
of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities
are sold pursuant to a registration statement, they will be sold only during such time
that the registration statement is effective and not withdrawn or suspended, and only as
permitted by the registration statement and in compliance with the plan of distribution
set forth therein, and acknowledges that the removal of the Restrictive Legend from certificates representing Securities as set
forth in this Section 4.8 is predicated upon the Company’s reliance upon this understanding.

 

    	 	-23-	 

     

    

 

4.9           Further
Assurances. Each party hereto agrees and covenants that at any time and from time to time it shall promptly execute and deliver
to the other party such further instruments and documents and take such further action as the other party may reasonably require
in order to carry out the full intent and purpose of this Agreement.

 

4.10         Equal
Treatment of Purchasers. No consideration (including any modification of any Transaction Document or any transaction document
executed in connection with any other securities purchase agreement entered into on the date hereof by and between the Company
and any purchaser of securities of the Company (collectively, the “Other SPAs”)) shall be offered or paid to
any Person to amend or consent to a waiver or modification of any provision of this Agreement (or the Other SPAs) unless the same
consideration is also offered to all of the parties to this Agreement or unless such consideration consists of warrants and a corresponding
adjustment to the applicable purchase price under the Other SPAs. For clarification purposes, this provision constitutes a separate
right granted to each applicable purchaser (including each Purchaser) by the Company and negotiated separately by such purchaser,
and is intended for the Company to treat the applicable purchasers (including each Purchaser) as a class and shall not in any way
be construed as such purchasers acting in concert or as a group with respect to the purchase, disposition or voting of the securities
of the Company or otherwise.

 

4.11         Right
to Designate Director.

 

		(a)	In addition to the transactions contemplated pursuant to
this Agreement, the Company agrees to:

 

		(i)	Contemporaneously with the Closing, (i) cause its Board
to increase the number of directors on the Board of Directors by one (1) director and (ii) appoint one (1) person nominated, collectively,
by Pontifax (China) IV Limited Partnership, Pontifax (Israel) IV Limited Partnership and Pontifax (Cayman) IV Limited Partnership
(collectively, “Pontifax” and, such person being nominated, the “Purchaser Nominee”, respectively)
as provided in this Section 4.11(a) to the Board of Directors, subject to the fulfillment of its fiduciary duties and the requirements
set forth in this Section 4.11; provided, that any such Purchaser Nominee shall be required to be independent, as defined by the
Nasdaq listing standards;

 

		(ii)	at each meeting of stockholders for election of directors
at which the position to be occupied under this Agreement by a Purchaser Nominee on the Board of Directors is to be determined
by stockholder election, (1) cause a Purchaser Nominee to be nominated by the Board of Directors for election as a director, subject
to the considerations described in clause (a)(i); (2) recommend to its stockholders the election of, and use its best efforts
to cause the election to, the Board of Directors, including soliciting proxies for the election of the Purchaser Nominee to the
same extent as it does, consistent with past practice, for any other Board nominee for election as a director; and (3) request
each then current member of the Board of Directors to vote as a stockholder for approval of the Purchaser Nominee.

 

    	 	-24-	 

     

    

 

		(b)	Any Purchaser Nominee shall not be nominated for election
or appointed to the Board of Directors unless he or she acknowledges and agrees to be bound by the principles set forth in the
Company’s Code of Conduct, and all other Company policies generally applicable to members of the Board of Directors as now
in effect or hereafter amended.

 

		(c)	In the event of the death, disability, resignation or removal
of the Purchaser Nominee, the Company shall cause the prompt election to the Board of Directors of a replacement director designated
by Pontifax, subject to the fulfillment of its fiduciary duties and the requirements set forth in this Section 4.11, to fill the
resulting vacancy, and such individual shall then be deemed a Purchaser Nominee for all purposes under this Agreement.

 

		(d)	So long as the Purchaser Nominee serves as a director on
the Board of Directors, the Purchaser Nominee shall be subject to and abide by the Company’s policies and procedures regarding
trading in the Company’s securities, including those involving blackout windows on trading, in each case, to the same extent
as other directors.

 

		(e)	If at any time Pontifax and its affiliates no longer beneficially
own in the aggregate at least 50% of the number of shares of Preferred Stock originally issued to Pontifax on the Closing Date
or at least 50% of the number of shares of Common Stock issued to Pontifax upon conversion of the Preferred Stock after the Stockholder
Filing (as adjusted for any stock splits, recapitalizations and similar transactions, its “Qualifying Ownership Interest”),
Pontifax will have no further rights under this Section 4.11, and, at the written request of the Board of Directors, shall use
its reasonable best efforts to cause the Purchaser Nominee to resign from the Board of the Directors within fifteen (15) calendar
days thereafter. Pontifax shall inform the Company if and when the Purchaser and its affiliates cease to hold its Qualifying Ownership
Interest.

 

		(f)	Any Purchaser Nominee then serving as a director shall
be entitled to the same indemnification in connection with his or her role as a director as the other members of the Board of
Directors (including Board committees, if applicable), and upon such Purchaser Nominee’s resignation or failure to stand
for re-election, such Purchaser Nominee shall be entitled to the same indemnification as any other former director of the Board
of Directors.

 

    	 	-25-	 

     

    

 

ARTICLE
V. 

MISCELLANEOUS

 

5.1           Termination.
This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before November 10, 2017; provided, however,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).

 

5.2           Fees
and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay (i) all Transfer
Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the
Company and any Exercise Notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the
delivery of any Securities to the Purchasers and (ii) all costs and expenses of its counsel in connection with the drafting and
negotiation of this Agreement.

 

5.3           Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or
written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4           Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
via facsimile or email attachment at the facsimile number or email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Business Day, (b) the next Business Day after the date of transmission, if such
notice or communication is delivered via facsimile or email attachment at the facsimile number or email address as set forth on
the signature pages attached hereto on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business
Day, (c) the second (2nd) Business Day following the date of mailing, if sent by
U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

5.5           Amendments;
Waivers. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by parties seeking amendment, or in the case of a waiver, by the party against whom the waiver
is to be effective. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. Any amendment effected in accordance with accordance with this Section 5.5 shall be binding only
upon such parties seeking such amendment.

 

    	 	-26-	 

     

    

 

5.6           Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.

 

5.7           Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the “Purchasers.”

 

5.8           No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

5.9           Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such suit, action or Proceeding by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof, effective upon receipt.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

5.10         Survival.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.

 

5.11         Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

    	 	-27-	 

     

    

 

5.12         Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.

 

5.13         Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has had the opportunity to be represented
by its own separate legal counsel or that of its investment manager in its review and negotiation of the Transaction Documents.
The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company
and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and
not between the Company and the Purchasers collectively and not between and among the Purchasers.

 

5.14         Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

5.15         Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement. The term “including” is deemed to mean “including, without limitation.”

 

    	 	-28-	 

     

    

 

5.16         WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

(Signature Pages Follow)

 

    	 	-29-	 

     

    

 

IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.

 

	ARQULE, INC.	 	Address for Notice:
	 	 	 
	By:	 	 	One Wall Street
	 	Name:	 	Burlington, MA 01803
	 	Title:	 	Fax:781-287-8143
	 	 	 
	 	 	With a copy to (which shall not constitute notice):
	 	 	 
	 	 	Richard E. Baltz
	 	 	Arnold & Porter Kaye Scholer LLP
	 	 	
        601 Massachusetts Avenue, N.W.

        Washington, D.C. 20001

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

     

     

    

 

[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE
AGREEMENT]

 

IN WITNESS WHEREOF, the
undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.

 

Name of Purchaser: ____________________________________________

Signature of Authorized Signatory of Purchaser:
_____________________

Name of Authorized Signatory: ___________________________________

Title of Authorized Signatory: ____________________________________

Email Address of Authorized Signatory: ____________________________

Facsimile Number of Authorized Signatory: __________________________

Address for Notice to Purchaser:

	 	 
	 	 
	 	 

 

Subscription Amount: $____________

Shares: ________________________

Warrant Shares: _________________

EIN Number: ____________________

 

[SIGNATURE PAGES CONTINUE]

 

     

     

    

 

Exhibit A

 

Form of Certificate of Designations of Series
A Preferred Stock of the Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]